- Home
- TPH vs ACAD Comparison
TPH vs ACAD Comparison
Compare TPH & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPH
- ACAD
- Stock Information
- Founded
- TPH 2009
- ACAD 1993
- Country
- TPH United States
- ACAD United States
- Employees
- TPH N/A
- ACAD N/A
- Industry
- TPH Homebuilding
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- TPH Consumer Discretionary
- ACAD Health Care
- Exchange
- TPH Nasdaq
- ACAD Nasdaq
- Market Cap
- TPH 2.8B
- ACAD 2.5B
- IPO Year
- TPH N/A
- ACAD 2004
- Fundamental
- Price
- TPH $31.78
- ACAD $16.93
- Analyst Decision
- TPH Strong Buy
- ACAD Buy
- Analyst Count
- TPH 5
- ACAD 15
- Target Price
- TPH $42.80
- ACAD $24.21
- AVG Volume (30 Days)
- TPH 1.2M
- ACAD 1.7M
- Earning Date
- TPH 04-24-2025
- ACAD 05-07-2025
- Dividend Yield
- TPH N/A
- ACAD N/A
- EPS Growth
- TPH 20.35
- ACAD N/A
- EPS
- TPH 4.51
- ACAD 1.37
- Revenue
- TPH $4,294,395,999.00
- ACAD $996,283,000.00
- Revenue This Year
- TPH N/A
- ACAD $13.07
- Revenue Next Year
- TPH $6.84
- ACAD $10.06
- P/E Ratio
- TPH $7.04
- ACAD $12.55
- Revenue Growth
- TPH 10.82
- ACAD 22.42
- 52 Week Low
- TPH $27.90
- ACAD $13.40
- 52 Week High
- TPH $47.78
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- TPH 56.87
- ACAD 64.73
- Support Level
- TPH $30.58
- ACAD $14.45
- Resistance Level
- TPH $31.84
- ACAD $15.31
- Average True Range (ATR)
- TPH 0.92
- ACAD 0.66
- MACD
- TPH 0.22
- ACAD 0.27
- Stochastic Oscillator
- TPH 85.10
- ACAD 90.91
About TPH Tri Pointe Homes Inc.
Tri Pointe Homes Inc is an American construction company that focuses on residential construction. The company is engaged in the design, construction, and sale of single-family attached and detached homes in different states across the United States. Its operations are organized into two principal businesses: homebuilding. which generates key revenue, and financial services. The homebuilding business has three reportable operating segments, based on the geographical layout of the markets, and includes West region, Central region, and East region. The company's financial services operation is comprised of its Tri Pointe Connect mortgage financing operations, Tri Pointe Assurance title and escrow services operations, and Tri Pointe Advantage property and casualty insurance agency operations.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.